Sean F.
- Country
- France
- Department
- Neurologie
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Phase III Open‑Label Single‑Arm Multicenter Study of On‑Body Delivery System for Subcutaneous High‑Concentration Ocrelizumab in Adults with Multiple Sclerosis
- A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis
Data & Insights
Has run more than one trial at 45 of 224 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the study and treatment of relapsing-remitting multiple sclerosis (RRMS), focusing on innovative therapeutic approaches in neurology.
- Multiple Sclerosis Management
- Neuroimmunology
- Autoimmune Disorders
Their research encompasses the evaluation of novel treatments for neurological conditions, particularly in the field of multiple sclerosis therapeutics.
Clinical Pharmacology
The investigator conducts research in pharmacokinetics and pharmacodynamics, with particular emphasis on biological therapies for neurological conditions.
- Therapeutic Drug Monitoring
- Biological Therapy Assessment
- Drug Safety Evaluation
Their work includes the assessment of therapeutic agents' behavior and effects in neurological disorders.
Neuroimaging
The investigator's expertise extends to brain lesion assessment and monitoring through advanced imaging techniques in multiple sclerosis.
- Brain Lesion Analysis
- Disease Progression Monitoring
- Therapeutic Response Assessment
Their research incorporates evaluation of neural tissue changes in response to therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.